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pt received September 19,he purpose of this study was to analyze the effect of beta blockade on outcome in patients with heart failure (HF)
and atrial ﬁbrillation (AF).Background Beta-blockers are widely used in patients with HF and AF. Recommendation in current HF guidelines, however, is
based on populations in which the most patients had sinus rhythm. Whether beta-blockers are as useful in AF is
uncertain.Methods Studies were included that investigated the effect of placebo-controlled, randomized beta-blocker therapy in
patients with AF at baseline and HF with reduced systolic left ventricular ejection fraction (LVEF) <40%.Results We identiﬁed 4 studies, which enrolled 8,680 patients with HF, and 1,677 of them had AF (19%; mean 68 years of
age; 30% women); there were 842 patients treated with beta-blocker, and 835 with placebo. In AF patients, beta-
blockade did not reduce mortality (odds ratio [OR]: 0.86 [95% conﬁdence interval (CI): 0.66 to 1.13]; p ¼ 0.28),
while in sinus rhythm patients, there was a signiﬁcant reduction (OR: 0.63 [95% CI: 0.54 to 0.73]; p < 0.0001).
Interaction analysis showed signiﬁcant interaction of the effects of beta-blocker therapy in AF versus that in sinus
rhythm (p ¼ 0.048). By meta-regression analysis, we did not ﬁnd confounding by all relevant covariates. Beta-
blocker therapy was not associated with a reduction in HF hospitalizations in AF (OR: 1.11 [95% CI: 0.85 to 1.47];
p ¼ 0.44), in contrast to sinus rhythm (OR: 0.58 [95% CI: 0.49 to 0.68]; p < 0.0001). There was a signiﬁcant
interaction of the effects of beta-blocker therapy in AF versus that in sinus rhythm (p < 0.001).Conclusions Our ﬁndings suggest that the effect of beta-blockers on outcome in HF patients with reduced systolic LVEF who have
AF is less than in those who have sinus rhythm. (J Am Coll Cardiol HF 2013;1:21–8) ª 2013 by the American
College of Cardiology FoundationBeta-blockers are a cornerstone treatment of patients with
heart failure (HF) (1). Randomized trials with carvedilol (U.S.
Carvedilol Study [2] and COPERNICUS [Carvedilol
Prospective Randomized Cumulative Survival] [3,4]),
metoprolol (MERIT-HF [Metoprolol CR/XL Randomised
Intervention Trial in Congestive Heart Failure] [5]),
bisoprolol (CIBIS-II [Cardiac Insufﬁciency Bisoprolol
Study II] [6]), and nebivolol (SENIORS [Study of Effects of
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2012; accepted September 20, 2012.in Seniors With Heart Failure] [7]) showed that beta-
blockers reduce morbidity and mortality in HF patients. As
a result, these agents have received a Class IA recommendation
in currentHFguidelines (1).Atrialﬁbrillation (AF) is common
in HF and occurs in 30% to 40% of all patients (8). The
HF trials that led to the recommendations also included
a proportion of patients with AF. In current guidelines for
HF therapy (1), the recommendation for beta-blockers is notSee page 29restricted to patients with sinus rhythm and includes all HF
patients (i.e., also for those withAF) but it is unknownwhether
beta-blockers are as effective in those patients as they are in
patients with sinus rhythm.
In patients with sinus rhythm with and without HF,
lower heart rate is associated with a better outcome (9–11)
and reduction of heart rate (by beta-blockers) probably
plays an important role in the beneﬁcial effect of these drugs.
Abbreviations
and Acronyms
AF = atrial ﬁbrillation
CI = conﬁdence interval
HF = heart failure
LVEF = left ventricular
ejection fraction
NYHA = New York Heart
Association
OR = odds ratio
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22In patients with AF, with or
without HF, lower heart rate,
however, is not associated with
a better outcome as was shown
recently (12).
Although patients with AF
were included in the large HF
trials, the absolute number of
patientswithAF in each individual
study was limited (13–16). The
aim of the present meta-analysis
therefore was to assess the effectof beta-blockade on outcome (i.e., mortality and hospitalization
for HF) in patients with both HF and AF.
Methods
Literature search. We searched MEDLINE using search
tools provided by PubMed and OVID. These search tools
have been validated by Haynes et al. (17) to optimize
retrieval. We used the keywords atrial ﬁbrillation, heart
failure, beta-blocker therapy, beta-blockade, and medical
therapy and a combination of these terms and included
papers published in English. Furthermore, we reviewed
reference lists from eligible studies, used the “see related
articles” feature for key publications in PubMed, consulted
the Cochrane Library, and searched the ISI Web of
Knowledge for publications that cited key publications.
Study selection. Studies were included that investigated
the effect of placebo-controlled, randomized beta-blocker
therapy in patients with AF documented by electrocardi-
ography (ECG) at baseline and HF with reduced systolic left
ventricular ejection fraction (LVEF) <40%. We restricted
our ﬁnal search to beta-blockers that are registered for HF
treatment (i.e., metoprolol, carvedilol, bisoprolol, nebivolol).
For this reason, one large outcome trial which examined
bucindolol (BEST [Beta-Blocker Evaluation of Survival
Trial]) was not included (18). One study (SENIORS
[Study of Effects of Nebivolol Intervention on Outcomes
and Rehospitalization in Seniors With Heart Failure])
included both patients with reduced and preserved LVEF.
For the present analysis, we included only patients with
LVEF <35%, because this was the cutoff value used in
that study, both in the methodology in the main study (7)
and in the separate publications of the 2 groups (19).
After study selection, we extracted data for the sinus
rhythm group for comparison with those for AF patients.
Articles were excluded if: 1) no data were available for
clinical outcomes; 2) data were published only in abstract
form; 3) no deﬁnition for HF was given, either by combina-
tion of symptoms and signs (using New York Heart Associ-
ation [NYHA] functional class or physical examination),
imaging (impaired LVEF), or a combination of both; and 4)
no distinction was made between AF and sinus rhythm. The
primary outcome measure was deﬁned as all-cause mortality.
The secondary outcome variable was hospital admission forworsening HF. For each study, we evaluated the effect of beta-
blocker treatment on both of these outcomes, separately, in
patients with AF and in those in sinus rhythm included.
Quality of studies in analysis. The quality of the indi-
vidual studies was assessed by 11 factors: 1) sufﬁciently
speciﬁed inclusion and exclusion criteria; 2) sufﬁcient
explanation of sample selection; 3) speciﬁcation of clinical
and demographic variables; 4) representation of the study
sample for the mentioned patient population; 5) speciﬁca-
tion of outcome measures; 6) deﬁnition of AF; 7) assessment
of the dose-response relationship between beta-blocker
therapy and outcome; 8) adjustment for possible con-
founders in the analysis; 9) reporting of rates of patients lost
to follow-up; 10) study design; and 11) duration of follow-
up. Grading was as follows: good quality included 8 to 11
criteria, fair quality included 5 to 7 criteria, and poor quality
included <5 criteria (20).
Statistical analysis. Meta-analysis was performed using
a ﬁxed-effects model to determine risk associated with
beta-blocker therapy and all-cause mortality as measured
by combined crude mortality rates. In secondary analysis,
hospital admission for HF was studied in a similar manner.
For comparison with patients in sinus rhythm, subgroup
analysis was carried out by testing of heterogeneity across
subgroups and by testing the null-hypothesis that the
proportion of total variation in subgroup estimates was due
to genuine variation across subgroups, rather than sampling
error. Second, we carried out interaction analysis between
subgroups of patients with AF and sinus rhythm, based on
methods described by Altman and Bland (21). Among
studies, heterogeneity of risk estimates was examined using
a standard chi-square test and I2 statistic for heterogeneity.
Reasons for diversity in study results were explored using
metaregression analysis. Variables explored included age,
sex, baseline rhythm, hypertension, diabetes, ischemic heart
disease, NYHA functional class, LVEF, heart rate, heart
rate reduction, blood pressure, and medical treatments,
including use of diuresis and digitalis and renin angiotensin
system inhibitor. Results are presented as odds ratios (ORs)
with 95% conﬁdence intervals (CIs) and p values. Evidence
of publication bias was assessed by visual inspection of the
funnel plot. A p value of <0.05 was considered statistically
signiﬁcant. Statistical analyses were performed using Stata
version 11.0 software (Stata, College Station, Texas) and
RevMan version 5.1 software (22).
Results
Study search and general characteristics. The search
retrieved 248 citations, 4 of which fulﬁlled all criteria as
they investigated the randomized allocation of beta-blocker
therapy in patients with HF and AF (Fig. 1). All these
reports were speciﬁc AF substudies of the large HF
outcome trials (U.S.-Carvedilol [13], CIBIS II [14],
MERIT-HF [15], and SENIORS [16]) that compared
the effect of beta-blockers with those of placebo. We were
Figure 1 QUORUM Flow Diagram
Quality of reporting of meta-analyses for study selection.
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23not able to retrieve data from one other large HF beta-
blocker study (COPERNICUS), because the presence of
AF documented at baseline was not reported (although new
onset AF was documented in 1 article) (4). Study quality was
scored as “good” for all but one, the U.S.-Carvedilol study,
which was scored as “fair.” All 4 studies reported the effect
on all-cause mortality, and 3 of the 4 studies also reported
HF hospitalizations.Table 1 Study Characteristics
First Author
Study (Ref. #) BB Year Follow-Up n (%)
Joglar et al.
U.S.-Carvedilol (13)
Carvedilol 2001 Maximum
400 days
AF: 136 (12%);
SR: 958
Lechat et al.
CIBIS-II (14)
Bisoprolol 2001 Maximum
800 days
AF: 521 (21%)
SR: 2,018
Van Veldhuisen et al.
MERIT-HF (15)
Metoprolol 2006 Mean F/U
1 yr
AF: 556 (14%);
SR: 3,132
Mulder et al.
SENIORS (16)*
Nebivolol 2011 Mean F/U
21 months
AF: 464 (22%);
SR: 895
*Only patients from the SENIORS trial with LVEF 35% were included.
BB ¼ beta-blocker; CCB ¼ calcium channel blockers; F/U ¼ follow-up; HF ¼ heart failure; LVEF ¼ lefThe main characteristics of the studies included in the
analysis are reported in Table 1. Overall, 8,680 patients were
included. Patient characteristics are shown in Table 2. In
total, 1,677 patients (19%) were in AF at baseline (mean
age, 68 years of age; 30% women), of whom 842 received
a beta-blocker and 835 received placebo. The other 7,003
patients (mean age 63 years; 24% women) had documented
sinus rhythm at baseline (3,640 in the beta-blocker groupTypes of Patients Endpoints Major Exclusion Criteria
HF;
LVEF 35%
All-cause mortality Unstable HF; heart
rate <68 beats/min;
Class I or III antiarrhythmic
drugs
HF;
LVEF 35%;
NYHA III–IV
All-cause mortality;
HF hospitalizations
Unstable HF; heart
rate <60 beats/min;
antiarrhythmic drugs other
than amiodarone
HF;
LVEF <40%;
NYHA II–IV
All-cause mortality;
HF; hospitalizations
Unstable HF; heart
rate <68 beats/min;
CCB or amiodarone
70 yrs of age;
HF admission
<1 yr or
LVEF 35%
All-cause mortality;
HF; hospitalizations
Unstable HF;
beta-blocker use
t ventricular ejection fraction; NYHA ¼ New York heart association; SR ¼ sinus rhythm.
Table 2 Patient Characteristics
First Author (Ref. #) AF/SR
Age
(yrs)
Men
(%)
HTN
(%)
DM
(%)
IHD
(%)
Stroke
(%)
LVEF
(%)
HR
(beats/min)
SBP
(mm Hg)
Digoxin
(%)
ACEi
(%)
Diuretics
(%)
Joglar et al. (13) AF 65 90 NA NA 51 NA 24 87 117 99 96 98
SR* 58 77 NA NA 48 NA 25 84 116 91 95 95
Lechat et al. (14) AF 62 83 17 13 25 12 27 88 131 85 96 98
SR 61 80 16 13 56 12 28 79 129 43 97 99
Van Veldhuisen et al. (15) AF 66 62 41 24 34 12 28 84 131 90 91 95
SR 63 76 44 25 51 8 28 82 130 59 89 90
Mulder et al. (16) AF 77 63 56 25 35 NA 28 84 136 70 83 92
SR 76 69 52 28 56 NA 29 77 136 30 79 86
*Sinus rhythm (SR) data were derived from the main study population.
ACEi ¼ angiotensin-converting enzyme inhibitors; DM ¼ history of diabetes; HR ¼ heart rate; HTN ¼ history of hypertension; IHD¼ ischemic heart disease; LVEF ¼ left ventricular ejection fraction; NA¼ not
available; SBP ¼ systolic blood pressure.
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24and 3,363 in the placebo group). Baseline heart rate, change
in heart rate, and achieved heart rate in each patient group
are shown in Table 3 and Figure 2 (no data were available
for the U.S.-Carvedilol study). Heart rate reduction in
patients in AF was similar to that in patients in sinus
rhythm, although the baseline heart rate was higher in
patients with AF. Doses of beta-blockers were similar in
CIBIS-II, MERIT-HF, and SENIORS (no data were
available for the U.S.-Carvedilol study).
All-cause mortality. Follow-up varied between a maximum
of 13 months in the U.S.-Carvedilol study to a mean of 21
months in the SENIORS trial. The crude mortality rates for
AF patients receiving beta-blocker therapy and those who
were not were 13.5% and 15.7%, respectively, and 8.3% and
13.1%, respectively, for sinus rhythm patients receiving beta-
blocker therapy and those who were not. This resulted in
a combined mortality risk OR of 0.86 for AF patients (95%
CI: 0.66 to 1.13; p ¼ 0.28) receiving beta-blocker therapy
versus a combined mortality risk OR of 0.63 for sinus rhythm
patients (95% CI: 0.54 to 0.73; p < 0.00001) receiving
beta-blocker therapy (Fig. 3). Interaction analysis showed
there was signiﬁcant interaction on the effect of beta-
blocker therapy in AF versus sinus rhythm (p ¼ 0.048).
There was no heterogeneity observed among the studies with
AF included (I2 ¼ 0%; p ¼ 0.46). In metaregression analysis,
we found no confounding by any of the variables explored.
Figure 4 shows the funnel plot for the main outcome analysis,
which shows no evidence of publication bias.Table 3 Baseline Heart Rate and Change in Heart Rate
First Author (Ref. #) Study
Assessment
of Baseline HR
Baseline HR
(beats/min)
Joglar et al. (13) U.S.-Carvedilol Unclear AF: 87
SR: 84*
Lechat et al. (14) CIBIS-II ECG AF: 88
SR: 79
Van Veldhuisen et al. (15) MERIT-HF ECG AF: 84
SR: 82
Mulder et al. (16) SENIORS ECG AF: 84
SR: 77
*Mean heart rate reduction in the main study population.
AF ¼ atrial ﬁbrillation; HR ¼ heart rate; ECG ¼ electrocardiogram; SR ¼ sinus rhythm.Hospital admission for heart failure. Three of the 4
studies (no data were available for the U.S.-Carvedilol trial)
reported the effect of beta-blocker therapy on hospital
admission for HF, including 7,586 HF patients (1,541
[20%] AF patients). Beta-blocker therapy in AF patients
was not associated with a reduction of HF hospitalizations
(16.2% vs. 14.8% events), resulting in anOR of 1.11 (95%CI:
0.85 to 1.47; p ¼ 0.44) (Fig. 5). For patients in sinus rhythm
(8.5% vs. 14.3% events), beta-blocker therapy was associated
with a reduction of HF hospitalizations (OR: 0.58 [0.49 to
0.68]; p < 0.0001). Interaction analysis showed a signiﬁcant
interaction on the effect of beta-blocker therapy in AF versus
sinus rhythm for HF hospitalizations (p < 0.001).Discussion
The main ﬁnding of the present meta-analysis indicates that
the effect of beta-blockers in patients with HF and AF is
signiﬁcantly different from the effect of these drugs in
patients with HF and sinus rhythm. Indeed, beta-blockers
were not found to have a favorable effect on HF hospitali-
zations or mortality in 1,677 AF patients who had been
enrolled in placebo-controlled, randomized studies.
This ﬁnding is important as most patients with HF
and AF receive beta-blocker treatment. Beta-blockade is
recommended in the current guidelines for HF and AF
treatment, albeit for different indications (1,23). In HF
treatment guidelines, beta-blockers are recommended for allAbsolute HR Reduction
Beta-Blocker (beats/min)
Relative HR Reduction
Beta-Blocker (%)
Beta-Blocker Dose
During Study
AF: 13.0
SR: 12.6*
AF: 14.9
SR: 15.0*
Unclear
AF: 8.8
SR: 10.6
AF: 10.1
SR: 13.5
Similar in both groups
AF: 14.8
SR: 13.7
AF: 17.6
SR: 16.7
Similar in both groups
AF: 11.0
SR: 10.9
AF: 13.1
SR: 14.2
Similar in both groups
Figure 2 Heart Rate and Heart Rate Reduction
Effect of beta-blocker therapy in patients with heart failure (HF) and atrial ﬁbrillation (AF) and in patients with HF and sinus rhythm.
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25patients in order to reduce morbidity and mortality, without
differentiation regarding rhythm. As such, these drugs are
part of the standard medical therapy for all patients with HF
and reduced LVEF. In addition, beta-blocker therapy has
been shown to prevent new onset or recurrent AF in patients
with HF (15,24) after myocardial infarction (25), and also in
a relatively low-risk (most hypertension) population (26).
In the AF treatment guidelines, however, beta-blockers
are recommended for rate control in order to reduceFigure 3 Combined All-Cause Mortality Risk
Effect of beta-blocker therapy in patients with HF and AF and in patients with HF and sinAF-related symptoms but not to improve prognosis (23). In
line with the guidelines are recent data from the CHARM
(Candesartan in Heart failure: Assessment of Reduction in
Mortality and Morbidity) program, which showed no
predictive value of higher heart rates in HF patients with
AF, in contrast to the observations in sinus rhythm
patients (11).
How can these different effects of beta-blockers between
HF patients with AF and sinus rhythm be explained? First,us rhythm. Abbreviations as in Figure 2.
Figure 4 Funnel Plot for the Main Analysis
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26heart rate reduction by beta-blocker therapy may be less
effective in patients with AF than in those with sinus
rhythm because the mode of action of beta-blockers is
different during AF and sinus rhythm. During sinus rhythm,
beta-blockers exert their heart rate lowering effect by
targeting the sinus node, whereas during AF their main site
of action is the atrioventricular node. In the present analysis,
however, we found a similar mean reduction in heart rate for
patients with both AF and sinus rhythm with comparable
dosages of beta-blockers; however, achieved heart rate was
not available and may have been different in AF and sinus
rhythm. Second, heart rates were measured only at rest.
Heart rate reduction during (moderate) exercise may haveFigure 5 Combined HF Hospitalization Risk
Effect of beta-blocker therapy in patients with HF and AF and in patients with HF and sinbeen different between AF and sinus rhythm patients.
Indeed, there may be differences in the optimal heart rate at
rest and during exercise and optimal heart rate reduction by
beta-blockers between both groups of patients. In patients
with sinus rhythm, it has been proven that a pronounced
reduction in heart rate is associated with improved morbidity
and mortality, independent of beta-blocker dose or by
additive therapy with selective If-channel blockade (9,10).
For patients with permanent AF, it was recently demon-
strated that stricter rate control was not superior to a
lenient rate control (12). Third, because of the loss of the
atrial kick and irregularity in ventricular response during
AF, patients with AF may need a higher heart rate to
maintain a similar cardiac output, possibly even more so
during HF (27). Fourth, a low heart rate in patients with
AF may be an expression of an underlying conduction
disorder, which may be associated with impaired outcome
itself. Finally, AF in patients with HF may be a marker of
a poorer clinical condition leading to a worse outcome, less
modiﬁable by beta-blocker treatment (28).
In addition to these potential explanations, we also cannot
exclude the fact that the present ﬁndings could apply to
some but not all beta-blockers, as differences in pharmaco-
logical proﬁles of beta-blockers may have played a role.
Metoprolol and bisoprolol are selective beta-1 receptor
antagonists, and carvedilol and nebivolol are beta-blockers
with additional vasodilating properties. A subanalysis of
the COMET (Carvedilol or Metoprolol European Trial)
(including 600 patients with AF) demonstrated that carve-
dilol had a better effect on outcome than metoprolol (29).
The main COMET has been criticized because the dose
of the 2 drugs might not have been comparable, as theyus rhythm. Abbreviations as in Figure 2.
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27lowered heart rate to a different extent. However, given the
absence of a relationship between heart rate lowering and
outcome in AF patients, this criticism may be less relevant
in this subpopulation of AF patients. It must be noted
that carvedilol had a relatively favorable effect in the
present analysis in the AF patients in the U.S.-Carvedilol
study (13), but these patients had milder disease than in
the other studies, which also may have affected the results.
Beta-blockers are standard therapy for HF. Other drugs
that are generally recommended for HF are angiotensin-
converting enzyme (ACE) inhibitors, angiotensin receptor
blockers, and aldosterone receptor blockers (or mineralo-
corticoid antagonists). It is remarkable that all these classes
of drugs have been shown to be at least as effective in
patients with AF as they are in patients with sinus rhythm
in analyses similar to the present study (28,30).
Study limitations. We conducted a meta-analysis of non–
pre-speciﬁed subgroups of large randomized trials, and this
analysis has some limitations that merit consideration.
Although the number of AF patients in the included
randomized studies was 1,677 with 145 events, this is still
low for survival analysis, and we cannot exclude the possi-
bility that lack of power may have played a role. On the other
hand, when ORs of beta-blocker therapy in AF patients
were similar to those in sinus rhythm patients, there would
have been sufﬁcient power to detect an effect as large as
found in sinus rhythm patients. However, if the effect of
beta-blocker therapy is attenuated in AF, larger sample sizes
are needed to draw deﬁnite conclusions. Nevertheless, there
was a signiﬁcant interaction with regard to this (beta-
blocker) treatment effect between AF and sinus rhythm
patients, which further supports our ﬁndings. Also, in the
present analysis, we pooled the effects of different beta-
blocker therapies and thereby assumed a class effect.
However, speciﬁc differences in pharmacologic proﬁles may
have added to the heterogeneity of our cohort and thereby
the results. Inherent limitations of pooled analysis of studies
include the limited availability of confounding variables,
including history of AF, duration of AF, pattern of AF
(paroxysmal vs persistent and/or permanent AF), new onset
AF, dose response, and tolerance to the drugs. In metare-
gression analysis, we explored possible study characteristics
that might have inﬂuenced the pooled estimates. However,
given the small number of studies included, we had only
limited power to ﬁnd signiﬁcant confounders. Finally, this
analysis pooled study group estimates and did not assess
individual patient data, which limits the possibility of
adjustment for individual patient characteristics.Conclusions
The present analysis suggests that the effect of beta-blockade
in HF patients with AF with regard to outcome is less than
in HF patients with sinus rhythm. Clearly, prospective
randomized controlled trials in HF speciﬁcally aiming at AFpatients are warranted to study the prognostic effects of
beta-blockers in this population.
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